IFNL3 · rs8103142
Where this position leads
Strength of the evidence
Its strongest genetic-study result is p = 10−12, with 2 associations in the GWAS Catalog.
4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.
What the study found
Who was studied 977 African American or Afro-Caribbean cases, 120,676 African American or Afro-Caribbean controls, 2,852 European ancestry cases, 447,587 European ancestry controls, 630 Hispanic or Latin American cases, 59,146 Hispanic or Latin American controls.
The effect Each copy of the T allele shifted the measure 0.16 lower (95% confidence interval 0.12-0.2); p = 3 × 10−12.
How common The T allele had a frequency of about 62% in the people studied.
Where it sits Chromosome 19, band 19q13.2 — a missense change in IFNL3.
What ClinVar records
Classification
Likely benign; criteria provided, multiple submitters, no conflicts (2 of 4 stars, 2 submitters), last evaluated 2018-03-09.
ClinVar record 511091 NM_172139.4(IFNL3):c.209A>G (p.Lys70Arg)
Change history MyGeneLog™ keeps a copy of every weekly release from 2026-10-19 and compares them. This position's classification has not changed since.
What this is ClinVar's aggregate record for this position (as of its 2026-10-19 release), not a result about you. A classification describes the variant against the condition named, as laboratories submitted it. Whether a person carries this variant, and what that would mean for them, is a question for a clinical test and a genetic counsellor.
rs8103142 is a single position in the genome, in or near the IFNL3 gene. Published research associates it with malignant neoplasm of liver, primary (phecode 155.1). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
IFNL3 carries pharmacogenomic findings for Peginterferon alfa and ribavirin. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
GWAS Catalog, Science (New York, N.Y.) 2024, PMID:39024449. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.
Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.
Malignant neoplasm of liver, primary (PheCode 155.1) (rs8103142). MyGeneLog™. https://www.mygenelog.com/variants/rs8103142